On November 2017, Nicox SA (Euronext Paris: FR0013018124, COX), the international ophthalmic company, reported that it will host a conference call on November 3. 2017, at 3pm CET/ 2pm UK/ 10 am ET following the announcement of the approval of VYZULTA by the U.S. FDA (Press release, NicOx, NOV 3, 2017, View Source [SID1234521545]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the conference call, please dial +33 (0)1 76 77 22 74 (France) or +44 (0)330 336 9105 or +1 323 794 2423 (International) and conference code number 5961849≠. You will be able to connect 10 minutes prior to the start time.

A slide presentation in PDF format can be accessed and will be archived on the "Events and Presentations" page of Nicox’s website www.nicox.com.

A replay of the conference call will be accessible approximately two hours following completion and will be available for 7days by dialing +33 (0)1 70 48 00 94 (France) or +44 (0)207 984 7568 or +1 719-457-0820 (International) and referencing conference confirmation code 5961849≠. The replay will also be available on the "Events and Presentations" page of Nicox’s website www.nicox.com.

Cerus has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, Cerus, 2017, NOV 3, 2017, View Source [SID1234521550]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 3, 2017 X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare diseases, reported that the first data from its ongoing Phase 1b clinical study of X4P-001-IO in patients with melanoma will be presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting on November 8-12 in National Harbor, MD (Press release, X4 Pharmaceuticals, NOV 3, 2017, View Source [SID1234521562]). A second poster highlighting the effects of CXCR4 inhibition in a syngeneic model of melanoma will also be presented.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The details of the poster presentations are as follows:

X4P-001, an Orally Bioavailable CXCR4 Antagonist, Increases T-cell Infiltration in Human Metastatic Melanoma
Friday, November 10, Abstract # P367, Session Category: Immune Modulation, Cytokines, and Antibodies

Efficacy and Mechanism of Action of CXCR4 Inhibition in B16-OVA Melanoma Model
Friday, November 10, Abstract # P356, Session Category: Immune Modulation, Cytokines, and Antibodies

About X4P-001-IO in Cancer

X4P-001-IO is an investigational selective, oral, small molecule inhibitor of CXCR4 (C-X-C receptor type 4) that regulates the tumor microenvironment, thereby enhancing endogenous anti-tumor responses. CXCR4 is a chemokine receptor that modulates immune function and angiogenesis through the trafficking of key immune cells such as T- cells, dendritic cells, and myeloid derived suppressor cells. CXCR4 signaling is disrupted in a broad range of cancers, facilitating tumor growth by allowing cancer cells to evade immune detection and creating a pro-tumor microenvironment. X4P-001-IO is being investigated in three separate clinical studies in solid tumors.

About Melanoma

Cutaneous malignant melanoma is the fifth most common cancer in men and the sixth most common cancer in women in the United States. When discovered early, melanoma is highly curable with 10-year overall survival rates approaching 95% for stage I melanoma and 45-77% for stage II melanoma.1 However, for patients with stage III and IV melanoma, the prognosis is much worse. The 10-year survival rate for stage IV melanoma is 10-15%.2 Adjuvant therapies for patients with resectable stage III melanoma include immunomodulating drugs, such as high dose interferon-α therapy and anti-CTLA-4 or PD-1 antibody therapy. Unmet medical needs remain to establish and improve overall survival in patients with advanced resectable melanoma, as well as improving objective response rates in patients who do not respond to existing treatments.

On November 3, 2017 Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), reported that Steven Klosk, President and Chief Executive Officer, will present at the Stephens Fall Investment Conference on November 8, 2017 at 10:00 a.m. EST in New York City (Press release, Cambrex, NOV 3, 2017, https://www.cambrex.com/cambrex-present-stephens-fall-investment-conference/ [SID1234521556]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Know more, wherever you are:
Latest on Cambrex Corporation’s Cancer Pipeline, book your free 1stOncology demo here.

The live audio webcast and slide presentation can be accessed from the Cambrex website at www.cambrex.com in the Investors section under "Webcasts & Presentations", and a replay will be available for 90 days after the live event concludes.

Genocea Biosciences has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, Genocea Biosciences, 2017, NOV 3, 2017, View Source [SID1234521559]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!